ReviewOncology letters2026
Mechanism-guided radiosensitization strategies for nasopharyngeal carcinoma: Current evidence and translational perspectives (Review).
Review in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nasopharyngeal carcinoma (NPC) is a distinct Epstein-Barr virus (EBV)-associated head and neck malignancy with a pronounced endemic distribution in Southern China and Southeast Asia. Intensity-modulated radiotherapy and concurrent chemoradiotherapy (CCRT) have substantially improved locoregional control; however, treatment failure remains common, particularly in locoregionally advanced, recurrent and metastatic disease. The present review summarizes mechanism-guided radiosensitization strategies for NPC according to clinical setting and translational maturity. Platinum-based CCRT remains the standard and most established radiosensitization approach. In selected patients with locoregionally advanced disease and a suboptimal response to induction chemotherapy, the addition of nimotuzumab to CCRT did not improve 2-year progression-free survival (81.0 vs. 80.8%; hazard ratio=0.93). By contrast, tislelizumab combined with chemotherapy markedly improved progression-free survival in recurrent or metastatic disease (hazard ratio=0.52), highlighting that systemic efficacy in this setting should not be conflated with radiosensitization during definitive radiotherapy. Consequently, epidermal growth factor receptor inhibition, DNA damage response targeting, hypoxia modification, immunoradiotherapy and EBV-directed therapies remain dependent on appropriate patient selection and prospective validation. Natural compounds and traditional Chinese medicine-derived agents are mechanistically promising but currently remain hypothesis-generating. Collectively, these approaches converge on key biological processes, including DNA repair, oxidative stress, apoptosis, epithelial-mesenchymal transition, hypoxia, EBV-associated signaling and immune remodeling. Plasma EBV DNA is currently the biomarker with the greatest clinical readiness for risk stratification, whereas most predictive biomarkers remain investigational. Key challenges include heterogeneous evidence quality, uncertain treatment sequencing and overlapping toxicities. Future treatment intensification should be biomarker-informed and tailored to disease stage, patient fitness and therapeutic index.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.